


**Pfizer Limited**

Pfizer Centre, Patel Estate,  
Off S. V. Road, Jogeshwari (W), Mumbai 400 102  
Tel 91 22 6693 2000 Fax 91 22 6693 2444

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2011**

(Rs In Lakhs)

Particulars	Quarter ended 30th September 2011	Quarter ended 31st August 2010	Half Year ended 30th September 2011	Six months ended 31st August 2010	Sixteen Months period ended 31st March 2011
	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. (a) Net Sales/Income from Operations	27,182	22,561	51,369	43,794	116,956
(b) Other Operating Income	1,802	1,242	3,736	2,487	7,508
2. Expenditure					
a. (Increase)/decrease in stock in trade and work in process	746	(1,517)	311	(2,751)	(3,215)
b. Consumption of raw materials (Refer note 4)	5,850	6,501	11,206	12,221	27,265
c. Purchase of traded goods	3,447	2,042	7,037	4,974	14,999
d. Employees cost	5,035	4,749	10,862	9,855	22,699
e. Depreciation	258	249	493	471	1,200
f. Other expenditure	8,743	6,796	16,335	13,129	36,824
g. Total	24,079	18,820	46,244	37,899	99,772
3. Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	4,905	4,983	8,861	8,382	24,692
4. Other Income	2,220	1,591	4,423	3,739	10,072
5. Profit before Interest and Exceptional Items (3+4)	7,125	6,574	13,284	12,121	34,764
6. Interest	-	-	-	-	-
7. Profit after Interest but before Exceptional Items (5-6)	7,125	6,574	13,284	12,121	34,764
8. Exceptional Items (Refer note 5)	-	(147)	-	(271)	(303)
9. Profit from Ordinary Activities before tax (7+8)	7,125	6,427	13,284	11,850	34,461
10. Tax expense	2,426	2,179	4,461	4,133	11,827
11. Net Profit from Ordinary Activities after tax (9-10)	4,699	4,248	8,823	7,717	22,634
12. Extraordinary Item (net of tax expense)	-	-	-	-	-
13. Net Profit for the period (11-12)	4,699	4,248	8,823	7,717	22,634
14. Paid-up equity share capital (Face Value per share Rs 10)	2,984	2,984	2,984	2,984	2,984
15. Reserves (excluding revaluation reserves which are NIL)					113,360
16. Earnings Per Share (EPS)					
(a) Basic and diluted EPS before exceptional Items for the period and for the previous year (not annualized) Rs.	15.75	14.56	29.57	26.45	76.52
(b) Basic and diluted EPS before extraordinary Items for the period and for the previous year (not annualized) Rs.	15.75	14.24	29.57	25.86	75.85
(c) Basic and diluted EPS after extraordinary Items for the period and for the previous year (not annualized) Rs.	15.75	14.24	29.57	25.86	75.85
17. Public Shareholding					
- No. of shares	8,728,269	8,728,269	8,728,269	8,728,269	8,728,269
- Percentage of shareholding	29.25%	29.25%	29.25%	29.25%	29.25%
18. Promoters and promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b) Non-encumbered					
- Number of Shares	21,113,171	21,113,171	21,113,171	21,113,171	21,113,171
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	70.75%	70.75%	70.75%	70.75%	70.75%

**UNAUDITED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED  
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2011**

(Rs In Lakhs)

Particulars	Quarter ended 30th September 2011	Quarter ended 31st August 2010	Half Year ended 30th September 2011	Six months ended 31st August 2010	Sixteen Months period ended 31st March 2011
	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Segment Revenue</b>					
(a) Pharmaceuticals	23,924	20,379	44,965	39,514	101,791
(b) Animal Health	3,258	2,888	6,404	5,651	15,920
(c) Services	1,766	1,089	3,669	2,288	7,392
<b>Total</b>	<b>28,948</b>	<b>24,356</b>	<b>55,038</b>	<b>47,453</b>	<b>125,103</b>
Less: Inter Segment Revenue	-	-	-	-	-
<b>Net sales/Income From Operations</b>	<b>28,948</b>	<b>24,356</b>	<b>55,038</b>	<b>47,453</b>	<b>125,103</b>
<b>2. Segment Results (Profit before tax and interest from each segment)</b>					
(a) Pharmaceuticals	5,855	6,686	10,249	11,479	28,403
(b) Animal Health	408	194	1,276	830	3,119
(c) Services	181	116	365	258	791
<b>Total</b>	<b>6,444</b>	<b>6,996</b>	<b>11,890</b>	<b>12,567</b>	<b>32,313</b>
Less: (i) Interest	(1,889)	(1,313)	(3,710)	(2,513)	(7,428)
(ii) Other un-allocable expenditure net off un-allocable income	1,208	1,882	2,316	3,230	5,280
<b>Total Profit Before Tax</b>	<b>7,125</b>	<b>6,427</b>	<b>13,284</b>	<b>11,850</b>	<b>34,461</b>
<b>3. Capital Employed</b>					
(a) Pharmaceuticals	9,552	10,066	9,552	10,066	10,989
(b) Animal Health	4,669	2,547	4,669	2,547	4,585
(c) Services	3,350	1,134	3,350	1,134	3,874
(d) Unallocated	107,596	97,648	107,596	97,648	96,896
<b>Total</b>	<b>125,167</b>	<b>111,395</b>	<b>125,167</b>	<b>111,395</b>	<b>116,344</b>

h

**NOTES:**

1. The above results were reviewed and recommended by Audit Committee for approval by the Board at its meeting held on 24th October, 2011 and were approved and taken on record at the meeting of the Board of Directors of the Company held on that date.
2. The results for the quarter ended 30<sup>th</sup> September, 2011 have been subjected to a limited review by the statutory auditors of the Company.
3. The company has changed its accounting year from 1st December - 30th November to 1st April - 31st March with effect from 1st December, 2009. The current quarter is from 1st July, 2011 to 30th September, 2011, while the previous quarter was from 1st June, 2010 to 31st August, 2010. The year to date figures for the current year are for the half year ended September 30, 2011 and year to date figures for the corresponding previous six months pertain to the six months ended August 31, 2010. Hence the figures are not strictly comparable. The previous year accounting period was for 16 months from 1st December, 2009 - 31st March, 2011.
4. "Consumption of raw materials" includes consumption of raw materials and packing materials.
5. "Exceptional items" include compensation paid to employees under VRS. The expense for the quarter ended 30<sup>th</sup> September, 2011 is Nil (previous year corresponding quarter ended 31<sup>st</sup> August, 2010 Rs 147 lakhs).
6. At the beginning of the current period, there were no shareholder complaints pending. During the current period 27 complaints were received and 27 complaints were disposed off. Hence, there is no complaint pending as at the end of the current period.
7. Charges towards provision of back office support to fellow subsidiaries, which were netted off against expenses amounting to Rs 133 Lakhs for the quarter ended 31<sup>st</sup> August, 2010 have now been regrouped to Other Operating Income. Consequential adjustments have been made to the segment disclosures.




UNAUDITED BALANCE SHEET AS ON 30<sup>TH</sup> SEPTEMBER, 2011

(Rs. in lakhs)

Particulars	30th September, 2011	31st August, 2010	31st March, 2011
	Unaudited	Unaudited	Audited
<b>SHAREHOLDERS' FUNDS:</b>			
(a) Capital	2,984	2,984	2,984
(b) Reserves & Surplus	122,183	108,411	113,360
<b>TOTAL</b>	<b>125,167</b>	<b>111,395</b>	<b>116,344</b>
<b>FIXED ASSETS</b>	<b>8,326</b>	<b>8,928</b>	<b>8,621</b>
<b>INVESTMENTS</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>DEFERRED TAX ASSET (NET)</b>	<b>3,922</b>	<b>3,309</b>	<b>3,554</b>
<b>CURRENT ASSETS, LOANS AND ADVANCES</b>			
(a) Inventories	16,717	13,193	15,932
(b) Sundry Debtors	13,225	10,066	9,819
(c) Cash and Bank Balances	87,717	59,160	57,701
(d) Other Current Assets	1,061	312	591
(e) Loans and Advances	18,373	37,302	42,127
Less: Current Liabilities and Provisions			
(a) Liabilities	18,261	16,582	15,719
(b) Provisions	5,913	4,293	6,282
<b>TOTAL</b>	<b>125,167</b>	<b>111,395</b>	<b>116,344</b>

For Pfizer Limited,


Kewal Handa  
Managing Director

Mumbai, 24th October, 2011